Please login to the form below

The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.

Gene therapies and research into them have grown immensely in recent years, offering more novel tools in regenerative medicine to fight disease, including rare diseases and genetic disorders. In the last decade, there has also been rapid development and interest in CRISPR/Cas9 technology and other gene-editing tools that could offer transformative avenues to deliver gene therapies for patients and families affected by devastating diseases such as sickle cell disease and thalassemia.

Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered with CRISPR Therapeutics to develop a gene-editing treatment for beta-thalassemia and sickle cell. In October 2022, the companies announced their plan to file exagamglogene autotemcel, the CRISPR/Cas9- edited therapy, for a rolling review with the FDA. Novartis also recently inked an up-to $1.5 billion deal with Precision Biosciences to support its development of one-time treatments for beta-thalassemia and sickle cell. The move marks a continuation in its ongoing commitment to exploring gene-editing technology.

Despite the surge of interest from both scientific and financial stakeholders, there remain numerous unique challenges at every step of this new frontier. From developing and financing the therapy in a timely manner to market access challenges due to the lack of maturity and extensive evidence, and explaining the complex science to physicians and patients, there are a variety of hurdles to overcome before bringing this type of technology to market. And while regenerative and curative therapies are often greatly lauded, there are also challenges in treating affected patient populations, including cost, accessibility, side effects, and other associated risks.

Earlier this year, the US Food and Drug Administration (FDA) approved the first potentially curative gene therapy to treat beta-thalassemia. While multiple companies have been working to bring transformative technologies such as CRISPR to market, approval will require further consideration around the many concerns and challenges of each stakeholder at every step. From the research and development stage all the way to patient access and treatment, remaining considerate of the populations that will ultimately be the end-users and testament to the technology’s success is vital.

Bringing in the patient perspective

Diagnosed with beta-thalassemia at six months old, Amar has had regular blood transfusions every few weeks for the majority of his life. As a child, he found himself falling behind others his age. “I always felt I was playing catch-up, through school, work, life—always making up for lost time,” he says.

Now in his 40s, he reflects on both the physical and mental impacts of the disease. He says, “As I’m getting older, my body is deteriorating, and it raises concerns for my future and what my life expectancy will look like. The disease has triggered other health conditions, including osteoarthritis, hypogonadism, and diabetes. It’s a constant challenge, both physically and mentally,” he says.

12th October 2022

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health